Dashboard
Manage Tickers

DYNDyne Therapeutics, Inc.

Nasdaq dyne-tx.com


$ 33.05 $ -0.62 (-1.84 %)    

Friday, 14-Jun-2024 15:59:56 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 479.30 $ 2.47 (0.52 %)
DIA $ 386.46 $ -0.42 (-0.11 %)
SPY $ 542.65 $ 0.33 (0.06 %)
TLT $ 94.67 $ 0.79 (0.84 %)
GLD $ 215.76 $ 2.76 (1.3 %)
$ 33.07
$ 32.67
$ 0.00 x 0
$ 0.00 x 0
$ 32.64 - $ 33.34
$ 6.40 - $ 35.98
579,553
na
2.68B
$ 0.86
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-02-2024 03-31-2024 10-Q
2 03-05-2024 12-31-2023 10-K
3 10-30-2023 09-30-2023 10-Q
4 08-03-2023 06-30-2023 10-Q
5 05-11-2023 03-31-2023 10-Q
6 03-02-2023 12-31-2022 10-K
7 11-03-2022 09-30-2022 10-Q
8 08-04-2022 06-30-2022 10-Q
9 05-02-2022 03-31-2022 10-Q
10 03-10-2022 12-31-2021 10-K
11 11-04-2021 09-30-2021 10-Q
12 08-05-2021 06-30-2021 10-Q
13 05-06-2021 03-31-2021 10-Q
14 03-04-2021 12-31-2020 10-K
15 11-05-2020 09-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

dyne-therapeutics-dyne-302-exhibited-prolonged-activity-in-preclinical-facioscapulohumeral-muscular-dystrophy-models-presents-data-during-fshd-society-international-research-congress
Dyne Therapeutics DYNE-302 Exhibited Prolo...
06/13/2024 20:43:53

caseys-reports-upbeat-earnings-joins-avidity-biosciences-rentokil-initial-and-other-big-stocks-moving-higher-on-wednesday
Casey's Reports Upbeat Earnings, Joins Avi...
06/12/2024 14:15:52

soft-inflation-data-boosts-small-caps-real-estate-regional-banks-traders-anticipate-fed-rate-cuts-as-stocks-react
Soft Inflation Data Boosts Small Caps, Rea...
06/12/2024 14:09:19

U.S. inflation slowed in May, boosting rate cut prospects. Markets rally ahead of FOMC meeting and assign 70% chance of rate cu...

modine-manufacturing-posts-mixed-q4-results-joins-viasat-lululemon-and-other-big-stocks-moving-lower-in-wednesdays-pre-market-session
Modine Manufacturing Posts Mixed Q4 Result...
05/22/2024 09:44:03

reported-earlier-dyne-therapeutics-prices-3255m-public-offering-of-105m-common-stock-at-31share
Reported Earlier, Dyne Therapeutics Prices...
05/22/2024 07:09:19

The gross proceeds to Dyne from the offering, before deducting underwriting discounts and commissions and offering expenses pay...

chardan-capital-maintains-buy-on-dyne-therapeutics-raises-price-target-to-42
Chardan Capital Maintains Buy on Dyne Ther...
05/21/2024 12:15:54

Chardan Capital analyst Keay Nakae maintains Dyne Therapeutics (NASDAQ:DYN) with a Buy and raises the price target from $31 ...

dyne-therapeutics-announces-300m-public-offering-of-common-stock
Dyne Therapeutics Announces $300M Public O...
05/20/2024 20:01:52

Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming...

why-is-dyne-therapeutics-stock-soaring-on-monday
Why Is Dyne Therapeutics Stock Soaring On ...
05/20/2024 19:53:38

Dyne Therapeutics reported promising Phase 1/2 trial data for DYNE-101 in myotonic dystrophy type 1 and DYNE-251 in Duchenne mu...

jefferies-maintains-buy-on-dyne-therapeutics-raises-price-target-to-42
Jefferies Maintains Buy on Dyne Therapeuti...
05/20/2024 17:32:17

Jefferies maintains Dyne Therapeutics (NASDAQ:DYN) with a Buy and raises the price target from $36 to $42.

overseas-shipholding-micron-squarespace-incyte-and-other-big-stocks-moving-higher-on-monday
Overseas Shipholding, Micron, Squarespace,...
05/20/2024 15:37:53

hc-wainwright--co-maintains-buy-on-dyne-therapeutics-raises-price-target-to-48
HC Wainwright & Co. Maintains Buy on Dyne ...
05/20/2024 13:33:21

HC Wainwright & Co. analyst Andrew Fein maintains Dyne Therapeutics (NASDAQ:DYN) with a Buy and raises the price target ...

Core News & Articles
Market-Moving News for May 20th
05/20/2024 12:37:59

PTCT: 27% | PTC Therapeutics Announces European Commission Returns Translarna Opinion to CHMP For Re-evaluation NKGN: 81% | NK...

dyne-therapeutics-announced-clinical-data-from-its-ongoing-phase-12-achieve-trial-of-dyne-101-in-myotonic-dystrophy-type-1-and-phase-12-deliver-trial-of-dyne-251-in-duchenne-muscular-dystrophy
Dyne Therapeutics Announced Clinical Data ...
05/20/2024 10:33:32

In Phase 1/2 ACHIEVE Trial, DYNE-101 Demonstrated Dose Dependent 27% Mean Splicing Correction Across All Patients in the 5.4 ...

reported-sunday-dyne-therapeutics-announces-virtual-event-to-unveil-new-clinical-data-from-achieve-and-deliver-trials
Reported Sunday, Dyne Therapeutics Announc...
05/20/2024 05:48:39

 Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transformin...

chardan-capital-maintains-buy-on-dyne-therapeutics-maintains-31-price-target
Chardan Capital Maintains Buy on Dyne Ther...
05/06/2024 12:03:57

Chardan Capital analyst Keay Nakae maintains Dyne Therapeutics (NASDAQ:DYN) with a Buy and maintains $31 price target.

oppenheimer-reiterates-outperform-on-dyne-therapeutics-maintains-47-price-target
Oppenheimer Reiterates Outperform on Dyne ...
05/06/2024 11:55:31

Oppenheimer analyst Francois Brisebois reiterates Dyne Therapeutics (NASDAQ:DYN) with a Outperform and maintains $47 price t...

hc-wainwright--co-reiterates-buy-on-dyne-therapeutics-maintains-36-price-target
HC Wainwright & Co. Reiterates Buy on Dyne...
05/03/2024 19:46:57

HC Wainwright & Co. analyst Andrew Fein reiterates Dyne Therapeutics (NASDAQ:DYN) with a Buy and maintains $36 price tar...

morgan-stanley-initiates-coverage-on-dyne-therapeutics-with-overweight-rating-announces-price-target-of-40
Morgan Stanley Initiates Coverage On Dyne ...
04/30/2024 09:17:22

Morgan Stanley analyst Michael Ulz initiates coverage on Dyne Therapeutics (NASDAQ:DYN) with a Overweight rating and announc...

oppenheimer-reiterates-outperform-on-dyne-therapeutics-maintains-47-price-target
Oppenheimer Reiterates Outperform on Dyne ...
03/26/2024 14:07:28

Oppenheimer analyst Francois Brisebois reiterates Dyne Therapeutics (NASDAQ:DYN) with a Outperform and maintains $47 price t...

why-landos-biopharma-shares-are-trading-higher-by-over-170-here-are-other-stocks-moving-in-mondays-mid-day-session
Why Landos Biopharma Shares Are Trading Hi...
03/25/2024 18:44:08

Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

06/28/2024 Malibu Boats, Inc. (MBUU)
07/01/2024 Globe Life Inc. f/k/a Torchmark Corporation (GL)
07/01/2024 Equinix, Inc. (EQIX)
07/02/2024 Intel Corporation (INTC)
07/05/2024 AXT, Inc. (AXTI)
07/05/2024 Altimmune, Inc. (ALT)
07/09/2024 Li Auto Inc. (LI)
07/12/2024 Inari Medical, Inc. (NARI)
07/12/2024 Sprout Social, Inc. (SPT)
07/15/2024 UnitedHealth Group Inc. (UNH)

NEW CASE INVESTIGATION

AnaptysBio Inc (ANAB)